PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

Ann: PARADIGM RECEIVES FEEDBACK FROM US FDA ON IND SUBMISSION, page-293

  1. 9,839 Posts.
    lightbulb Created with Sketch. 1258
    Thanks for sharing such personal information

    My perception is that the words "slow the progress of the disease" recently used by PR on release of 6 month top line for OA008 will become the new mantra.

    Delaying TKR for your wife is an outstanding outcome clinical outcome given her relative age and ability to enjoy her life (golf) over the past 5 years.

    The application of iPPS to the wider masses would likely only get the nod if it wasn't classified as an aggressive treatment protocol. A complete remission of OA would likely have significant associated SAE like Humira has seen with RA.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.